Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gabapentin + morphine is a combination therapy involving the anticonvulsant gabapentin and the opioid analgesic morphine. This combination is primarily used for the management of neuropathic pain and severe cancer pain, especially in cases where monotherapy with either agent is insufficient. Gabapentin acts by modulating voltage-gated calcium channels, reducing excitatory neurotransmitter release, while morphine exerts its effects as an agonist at the mu-opioid receptor to inhibit pain signaling in the central nervous system. Clinical studies have shown that combining these drugs can provide better analgesia at lower doses than either drug alone, potentially reducing opioid requirements[1][2][4][8]. However, this combination increases risks of central nervous system depression and respiratory depression due to additive effects[3][5]. The use of this combination should be carefully monitored due to these safety concerns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin + morphine.